In vitro studies of the combination of imatinib mesylate (Gleevec) and arsenic trioxide (Trisenox) in chronic myelogenous leukemia

Paul La Rosée, Kara Johnson, Michael E. O'Dwyer, Brian Druker

Research output: Contribution to journalArticle

89 Citations (Scopus)

Abstract

Objective. The aim of this study was the preclinical evaluation of imatinib mesylate (Gleevec, formerly STI571) in conjunction with arsenic trioxide (As 2O 3, Trisenox) for the treatment of chronic myelogenous leukemia (CML). Materials and Methods. Tetrazolium-based cell line proliferation assays (MTT assays) were performed to determine the cytotoxicity of As 2O 3 alone and in combination with imatinib. Cell lines tested in this study were Bcr-Abl-expressing cells (K562, MO7p210, 32Dp210) and parental cells (MO7e, 32D). Isobologram analysis was performed manually and using the median effect method. In vitro cytotoxicity also was determined in colony-forming assays using CML patient cells. Western blot analysis was performed to detect Bcr-Abl protein levels in K562 cells exposed to As 2O 3 at graded concentrations. Bcr-Abl protein level kinetics were correlated with cell viability (trypan blue count) and activated caspase-3 detected by flow cytometry. Results. We show additive to synergistic cytotoxicity in Bcr-Abl + cell lines depending on inhibitory concentrations and cell type. Results obtained by colony-forming assays confirmed the findings in cell line proliferation assays. Flow cytometric detection of activated caspase-3 revealed synergistic activity in K562 cells. Treatment of K562 cells with As 2O 3 alone led to down-regulation of Bcr-Abl protein within 24 hours, even at low doses. The decline of Bcr-Abl preceded activation of caspase-3 and the loss of viable cells. Conclusions. Favorable cytotoxicity and proapoptotic activity of imatinib in conjunction with As 2O 3 and specific down-regulation of Bcr-Abl protein levels by As 2O 3 in K562 cells indicate that As 2O 3 in combination with imatinib might be useful for circumventing resistance to imatinib monotherapy.

Original languageEnglish (US)
Pages (from-to)729-737
Number of pages9
JournalExperimental Hematology
Volume30
Issue number7
DOIs
StatePublished - 2002

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
K562 Cells
Caspase 3
Cell Line
Proteins
Down-Regulation
Cell Proliferation
Trypan Blue
arsenic trioxide
In Vitro Techniques
Imatinib Mesylate
Cell Survival
Flow Cytometry
Western Blotting
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Cell Biology
  • Genetics
  • Hematology
  • Oncology
  • Transplantation

Cite this

In vitro studies of the combination of imatinib mesylate (Gleevec) and arsenic trioxide (Trisenox) in chronic myelogenous leukemia. / La Rosée, Paul; Johnson, Kara; O'Dwyer, Michael E.; Druker, Brian.

In: Experimental Hematology, Vol. 30, No. 7, 2002, p. 729-737.

Research output: Contribution to journalArticle

@article{dd58218d3c33421a88c0e531f886b370,
title = "In vitro studies of the combination of imatinib mesylate (Gleevec) and arsenic trioxide (Trisenox) in chronic myelogenous leukemia",
abstract = "Objective. The aim of this study was the preclinical evaluation of imatinib mesylate (Gleevec, formerly STI571) in conjunction with arsenic trioxide (As 2O 3, Trisenox) for the treatment of chronic myelogenous leukemia (CML). Materials and Methods. Tetrazolium-based cell line proliferation assays (MTT assays) were performed to determine the cytotoxicity of As 2O 3 alone and in combination with imatinib. Cell lines tested in this study were Bcr-Abl-expressing cells (K562, MO7p210, 32Dp210) and parental cells (MO7e, 32D). Isobologram analysis was performed manually and using the median effect method. In vitro cytotoxicity also was determined in colony-forming assays using CML patient cells. Western blot analysis was performed to detect Bcr-Abl protein levels in K562 cells exposed to As 2O 3 at graded concentrations. Bcr-Abl protein level kinetics were correlated with cell viability (trypan blue count) and activated caspase-3 detected by flow cytometry. Results. We show additive to synergistic cytotoxicity in Bcr-Abl + cell lines depending on inhibitory concentrations and cell type. Results obtained by colony-forming assays confirmed the findings in cell line proliferation assays. Flow cytometric detection of activated caspase-3 revealed synergistic activity in K562 cells. Treatment of K562 cells with As 2O 3 alone led to down-regulation of Bcr-Abl protein within 24 hours, even at low doses. The decline of Bcr-Abl preceded activation of caspase-3 and the loss of viable cells. Conclusions. Favorable cytotoxicity and proapoptotic activity of imatinib in conjunction with As 2O 3 and specific down-regulation of Bcr-Abl protein levels by As 2O 3 in K562 cells indicate that As 2O 3 in combination with imatinib might be useful for circumventing resistance to imatinib monotherapy.",
author = "{La Ros{\'e}e}, Paul and Kara Johnson and O'Dwyer, {Michael E.} and Brian Druker",
year = "2002",
doi = "10.1016/S0301-472X(02)00836-6",
language = "English (US)",
volume = "30",
pages = "729--737",
journal = "Experimental Hematology",
issn = "0301-472X",
publisher = "Elsevier Inc.",
number = "7",

}

TY - JOUR

T1 - In vitro studies of the combination of imatinib mesylate (Gleevec) and arsenic trioxide (Trisenox) in chronic myelogenous leukemia

AU - La Rosée, Paul

AU - Johnson, Kara

AU - O'Dwyer, Michael E.

AU - Druker, Brian

PY - 2002

Y1 - 2002

N2 - Objective. The aim of this study was the preclinical evaluation of imatinib mesylate (Gleevec, formerly STI571) in conjunction with arsenic trioxide (As 2O 3, Trisenox) for the treatment of chronic myelogenous leukemia (CML). Materials and Methods. Tetrazolium-based cell line proliferation assays (MTT assays) were performed to determine the cytotoxicity of As 2O 3 alone and in combination with imatinib. Cell lines tested in this study were Bcr-Abl-expressing cells (K562, MO7p210, 32Dp210) and parental cells (MO7e, 32D). Isobologram analysis was performed manually and using the median effect method. In vitro cytotoxicity also was determined in colony-forming assays using CML patient cells. Western blot analysis was performed to detect Bcr-Abl protein levels in K562 cells exposed to As 2O 3 at graded concentrations. Bcr-Abl protein level kinetics were correlated with cell viability (trypan blue count) and activated caspase-3 detected by flow cytometry. Results. We show additive to synergistic cytotoxicity in Bcr-Abl + cell lines depending on inhibitory concentrations and cell type. Results obtained by colony-forming assays confirmed the findings in cell line proliferation assays. Flow cytometric detection of activated caspase-3 revealed synergistic activity in K562 cells. Treatment of K562 cells with As 2O 3 alone led to down-regulation of Bcr-Abl protein within 24 hours, even at low doses. The decline of Bcr-Abl preceded activation of caspase-3 and the loss of viable cells. Conclusions. Favorable cytotoxicity and proapoptotic activity of imatinib in conjunction with As 2O 3 and specific down-regulation of Bcr-Abl protein levels by As 2O 3 in K562 cells indicate that As 2O 3 in combination with imatinib might be useful for circumventing resistance to imatinib monotherapy.

AB - Objective. The aim of this study was the preclinical evaluation of imatinib mesylate (Gleevec, formerly STI571) in conjunction with arsenic trioxide (As 2O 3, Trisenox) for the treatment of chronic myelogenous leukemia (CML). Materials and Methods. Tetrazolium-based cell line proliferation assays (MTT assays) were performed to determine the cytotoxicity of As 2O 3 alone and in combination with imatinib. Cell lines tested in this study were Bcr-Abl-expressing cells (K562, MO7p210, 32Dp210) and parental cells (MO7e, 32D). Isobologram analysis was performed manually and using the median effect method. In vitro cytotoxicity also was determined in colony-forming assays using CML patient cells. Western blot analysis was performed to detect Bcr-Abl protein levels in K562 cells exposed to As 2O 3 at graded concentrations. Bcr-Abl protein level kinetics were correlated with cell viability (trypan blue count) and activated caspase-3 detected by flow cytometry. Results. We show additive to synergistic cytotoxicity in Bcr-Abl + cell lines depending on inhibitory concentrations and cell type. Results obtained by colony-forming assays confirmed the findings in cell line proliferation assays. Flow cytometric detection of activated caspase-3 revealed synergistic activity in K562 cells. Treatment of K562 cells with As 2O 3 alone led to down-regulation of Bcr-Abl protein within 24 hours, even at low doses. The decline of Bcr-Abl preceded activation of caspase-3 and the loss of viable cells. Conclusions. Favorable cytotoxicity and proapoptotic activity of imatinib in conjunction with As 2O 3 and specific down-regulation of Bcr-Abl protein levels by As 2O 3 in K562 cells indicate that As 2O 3 in combination with imatinib might be useful for circumventing resistance to imatinib monotherapy.

UR - http://www.scopus.com/inward/record.url?scp=0036320754&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036320754&partnerID=8YFLogxK

U2 - 10.1016/S0301-472X(02)00836-6

DO - 10.1016/S0301-472X(02)00836-6

M3 - Article

C2 - 12135670

AN - SCOPUS:0036320754

VL - 30

SP - 729

EP - 737

JO - Experimental Hematology

JF - Experimental Hematology

SN - 0301-472X

IS - 7

ER -